Recent news coverage includes broad market and commodity price movements but no company-specific developments for Nymox Pharmaceutical Corp.

• Stocks have slumped due to AI slowdown fears and rising bond yields and crude prices [N1].
• Corn trading showed midday gains [N2].
• Cocoa prices gained on the outlook for tighter supplies from Ghana [N3].
• Stocks fell amid AI slowdown fears and rising crude oil prices [N4].
• Soybeans faced pressure as USDA increased production estimates [N5].
• Cattle prices rallied on Monday [N6].
• Hogs prices fell on Monday [N7].
• Brazilian real weakness weighed on sugar prices [N8].

The company’s focus on NX-1207, a therapeutic candidate for BPH and prostate cancer, represents a potential value driver if clinical trials demonstrate efficacy and safety, leading to regulatory approval and market launch. The company’s existing patents and research collaborations provide a foundation for product development. Management’s efforts to control costs, as seen in reduced research and development expenditures, may help extend the company’s financial runway. The re-election of the board of directors indicates governance continuity. If the company successfully navigates clinical and regulatory hurdles and secures necessary financing, it could advance toward commercialization.

Nymox faces substantial risks including continued operating losses, lack of product revenues, and a low liquidity position with a current ratio of 0.09 as of December 31, 2024. The company’s research and development activities are subject to significant uncertainty related to clinical trial outcomes, regulatory approvals, and manufacturing capabilities. The need for additional financing introduces dilution risk and potential operational constraints. The absence of marketing activities and the early stage of product development limit near-term revenue visibility. Cybersecurity and other operational risks could further impact the company’s business. Overall, the company’s financial and operational challenges present material risks to its business model execution.

Nymox’s potential competitive advantage lies in its proprietary therapeutic candidates, particularly NX-1207, which is in clinical development for BPH and prostate cancer. The company holds patents and has research and license agreements with institutions such as Massachusetts General Hospital and Rhode Island Hospital. However, the company faces significant challenges typical of early-stage pharmaceutical firms, including the high costs and long timelines of clinical trials, regulatory approval uncertainty, and the need for partnerships to commercialize products. The absence of current revenues and the reliance on external financing limit the visibility of its competitive moat at this stage.

• Clinical and Regulatory Risk: The company’s therapeutic candidates are in early-stage development with uncertain clinical trial outcomes and regulatory approval timelines, which could delay or prevent product commercialization.
• Liquidity and Financing Risk: The company’s current liquidity position is weak, with a current ratio of 0.09 as of December 31, 2024, and management acknowledges the need for additional financing to support operations, which may not be available on favorable terms.
• Operational Risk: Risks include cybersecurity breaches, disruptions to information systems, and the ability to manufacture products in compliance with regulatory standards and at commercial scale.
• Market and Commercialization Risk: The company has no current revenues and marketing activities are minimal; successful product launch depends on clinical success and potential partnerships, which are uncertain.

• Nymox Pharmaceutical Corp is a pharmaceutical company focused on developing therapeutic candidates, notably NX-1207 for BPH and prostate cancer.
• The company has incurred substantial operating losses since inception, primarily due to research and development expenditures.
• As of December 31, 2025, the company had an accumulated deficit of $216.7 million.
• The company reported no revenues from sales of goods for the years ended December 31, 2024 and 2025.
• Research and development expenses were $1.48 million in 2025 and $3.28 million in 2024, mainly related to clinical trials and regulatory compliance for NX-1207.
• Marketing expenses were nil for 2024 and 2025, with plans to increase marketing if products reach the market stage.
• General and administrative expenses increased to $2.19 million in 2025 from $1.00 million in 2024, driven by stock-based compensation and professional fees.
• Finance costs increased to $587,440 in 2025 from $208,668 in 2024, mainly due to finance charges and amortization of convertible loan components.
• The company’s liquidity as of December 31, 2024, shows cash and equivalents of $4.07 million, current assets of $653,000, and current liabilities of $7.43 million, resulting in a current ratio of 0.09 and a cash ratio of 0.55.
• Management acknowledges that current cash and anticipated product sales are insufficient to fund planned operations over the next 12 months and intends to seek additional financing if needed.
• The company’s board oversees risk management including cybersecurity risks.
• The company’s financial statements are prepared under IFRS and audited.
• Shareholders elected the board of directors in August 2026.
• Recent news coverage includes general market and commodity price movements but no company-specific developments.